|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12,632.00 GBX | -0.69% |
|
-0.30% | -8.40% |
| 01:17pm | AstraZeneca In Talks for $400 Billion Combination With US Peer BMS | MT |
| 03/08 | AstraZeneca held talks with Bristol Myers Squibb on $400 billion megadeal, source says | RE |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Pharmaceuticals
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 264B | |||||
| 1,024B | |||||
| 618B | |||||
| 443B | |||||
| 349B | |||||
| 297B |
- Stock Market
- Stocks
- AZN Stock
- Charts AstraZeneca PLC
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
